Core Insights - ProMIS Neurosciences has completed enrollment for its PRECISE-AD Phase 1b trial, with 144 patients enrolled, exceeding the target of 128, indicating strong interest in PMN310's therapeutic potential [3][8] - The company reported a net loss of $39.7 million for the year ended December 31, 2025, with cash reserves of $6.1 million, reflecting its investment in advancing the PRECISE-AD trial [12][24] - PMN310 has shown a favorable safety profile with no treatment-related serious adverse events reported to date, and it is designed to minimize treatment-related side effects, particularly Amyloid-Related Imaging Abnormalities (ARIA) [4][15] Clinical Development - The PRECISE-AD trial is expected to complete six-month assessments in Q2 2026, with a blinded interim analysis anticipated in early Q3 2026 and top-line data expected in early 2027 [1][9] - PMN310 has been granted Fast Track Designation by the FDA, which may facilitate its development and regulatory engagement [7][15] - The company is also developing a subcutaneous formulation of PMN310 to improve patient experience and strengthen its competitive profile [6][13] Financial Overview - The company closed a financing round in early 2026, raising up to $175 million, which includes $75 million upfront and $100 million tied to future warrant exercises, providing a cash runway through 2027 [6][12] - Research and development expenses for 2025 were $33.4 million, significantly higher than the $10.6 million in 2024, primarily due to costs associated with the PRECISE-AD trial [12][24] - General and administrative expenses increased to $6.8 million in 2025 from $6.2 million in 2024, driven by a moderate increase in employee headcount [12][24] Pipeline and Future Directions - PMN267 and PMN442 are other key pipeline candidates targeting amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), respectively, with PMN267 showing selectivity for pathogenic TDP-43 and PMN442 targeting alpha-synuclein [13][14] - The company is monitoring developments in preclinical and asymptomatic Alzheimer's disease trials, considering potential expansion into these areas based on PMN310's safety profile [8]

Core Insights - ProMIS Neurosciences has received Fast Track designation from the U.S. FDA for its Alzheimer's disease treatment candidate PMN310, enhancing its potential for priority review [2][11] - The PRECISE-AD Phase 1b trial for PMN310 is progressing well, with over 50% of the planned 128 patients enrolled, no cases of amyloid-related imaging abnormalities (ARIA) reported, and no patient dropouts [2][9] - The company has strengthened its financial position by raising approximately $21.6 million in gross proceeds in July 2025 [2][14] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapeutics targeting toxic misfolded proteins associated with neurodegenerative diseases, including Alzheimer's disease, ALS, and Parkinson's disease [10] - The company's proprietary platform, EpiSelect™, is designed to identify conformational epitopes on toxic misfolded proteins, enabling the generation of selective therapeutic antibodies [4][10] Clinical Development - PMN310 is a humanized IgG1 monoclonal antibody specifically targeting toxic amyloid-beta oligomers (AβO), which are believed to be a major driver of Alzheimer's disease [5][11] - The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, and pharmacokinetics of PMN310, with interim results expected in Q2 2026 and final results in Q4 2026 [12][9] Financial Performance - As of June 30, 2025, ProMIS reported cash and cash equivalents of $4.5 million, an increase from $1.0 million a year earlier [14] - Research and development expenses for Q2 2025 were $8.7 million, significantly higher than $1.6 million in the same period of 2024, primarily due to costs associated with the PRECISE-AD trial [14][20] - The net loss for Q2 2025 was $10.1 million, compared to a net loss of $2.6 million in Q2 2024, reflecting increased clinical trial expenditures [14][20]

Core Insights - ProMIS Neurosciences Inc. is advancing its lead clinical program PMN310 for Alzheimer's disease, with significant progress in patient enrollment for the PRECISE-AD trial, which is expected to yield interim results in the first half of 2026 and topline results by the end of 2026 [1][2][4] Alzheimer's Disease Program (PMN310) - PMN310 is a humanized IgG1 antibody targeting toxic amyloid-beta oligomers, which are believed to drive Alzheimer's disease [3] - The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with a planned enrollment of approximately 128 patients across 22 sites in the U.S. [3] - The trial aims to assess the incidence of ARIA (Amyloid-related imaging abnormalities) and other biomarkers, with a primary focus on safety [3][4] - The interim analysis in 2026 will provide early insights into PMN310's potential clinical benefits and tolerability [2][4] Financial Highlights - As of March 31, 2025, ProMIS reported cash and cash equivalents of $8.4 million, down from $13.3 million at the end of 2024 [12] - Research and development expenses increased to $5.5 million in Q1 2025, compared to $2.1 million in Q1 2024, primarily due to costs associated with the PMN310 Phase 1b clinical trial [12] - The net loss for Q1 2025 was $7.3 million, compared to a net loss of $3.6 million in the same period of 2024 [12][18] Other Programs - ProMIS is also advancing its Aβ vaccine program (PMN311) and has initiated a program targeting toxic misfolded TDP-43 for amyotrophic lateral sclerosis (PMN267) [4][5] - The company presented preclinical data at major conferences, highlighting the potential of its vaccine candidates to selectively target toxic oligomers and misfolded proteins associated with neurodegenerative diseases [7][8]

Core Insights - ProMIS Neurosciences is advancing its lead antibody candidate PMN310 for Alzheimer's disease (AD) through a Phase 1b clinical trial, highlighting the urgent need for improved treatment options in the AD space [1][2][3] - The company reported a net income of $2.8 million for the fiscal year 2024, a significant turnaround from a net loss of $13.2 million in 2023, primarily due to a gain on the change in fair value of warrant liabilities [7][14] - ProMIS has expanded its intellectual property portfolio with 23 newly granted or allowed patents since January 2024, strengthening its position in the neurodegenerative disease market [2][3] Alzheimer's Disease Program (PMN310) - PMN310 is a humanized IgG1 antibody targeting toxic amyloid-beta oligomers, which are believed to drive AD progression [3][4] - The Phase 1b trial (PRECISE-AD) aims to enroll approximately 100 subjects across 22 sites in the U.S., with interim results expected in the first half of 2026 and topline results anticipated by the end of 2026 [3][4] - The Phase 1a trial demonstrated that PMN310 was well-tolerated and effectively crossed the blood-brain barrier, suggesting potential for target engagement in AD patients [4] Financial Highlights - As of December 31, 2024, ProMIS had cash and cash equivalents of $13.3 million, an increase from $12.6 million in 2023 [7][11] - Research and development expenses rose to $10.6 million in 2024 from $7.9 million in 2023, reflecting costs associated with clinical trials [7][14] - The company completed a PIPE financing in Q3 2024, providing initial funding of $30.3 million and potential additional funding of $92.4 million [7] Pipeline and Future Developments - ProMIS is also advancing programs for amyotrophic lateral sclerosis (ALS) with PMN267 and multiple synucleinopathies with PMN440, showcasing a diverse pipeline in neurodegenerative diseases [2][5][6] - The company plans to present preclinical data at upcoming conferences, further demonstrating its commitment to innovation in the field [4][5][6]